Adjudicated CN SSE
Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances
Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.
CASE PROFILE & BENCHMARKS
- Target Issuer: Kangmei Pharmaceutical Co., Ltd. (CN).
- Fraud Period: January 1, 2019 to December 31, 2021.
- Reported Overstatement: $4.4B.
- Total Fines & Penalties: $350.0M.
- Maximum Incarceration: No prison sentence.
- Independent Auditor: Ernst & Young LLP.
- Primary Schemes: fictitious cash and assets.
- Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $4.4B USD reported
TOTAL PENALTIES $350.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2021 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR China Securities Regulatory Commission (CSRC) CN
FORENSIC ACCOUNTING AUTOPSY & MECHANICS
COMPREHENSIVE MULTI-PHASE INVESTIGATION| Forensic Dimension | Investigative Finding & Evidentiary Record |
|---|---|
| Executive Motive & Pressure | Kangmei Pharmaceutical was a flagship blue-chip constituent of China's CSI 300 index, celebrated for rapid growth in traditional Chinese medicine supply chains. To sustain its valuation and fund related-party real estate ventures controlled by founder Ma Xingtian, the company systematically fabricated revenues, inventory, and cash balances from 2016 through 2018. |
| Auditor Blind Spots & Breakdown | GP Certified Public Accountants issued clean audit opinions across multiple years without independently reconciling bank confirmation responses against central clearing records, failing to question why a company claiming $5B in idle cash needed to borrow billions at high interest rates. |
| Detection Catalyst & Unraveling | Following a CSRC investigation triggered by debt repayment stress and 'cash-rich yet borrowing-heavy' anomalies, Kangmei stunned markets in April 2019 by wiping 30B yuan of cash off its balance sheet. In 2021, a Guangzhou court issued China's first landmark securities class-action judgment of 2.46B yuan and sentenced Ma Xingtian to 12 years in prison. |
| Screening & Prevention Takeaway | The Cash-vs-Debt Paradox: Whenever an issuer reports massive idle cash balances earning low deposit yields while simultaneously issuing high-yield bonds or short-term commercial paper, the reported cash is often encumbered, pledged, or completely fictitious. |
| Statutory Violations & Charges | PRC Securities Law Article 63 & Criminal Law Article 161 (False Financial Reporting) Guangzhou Intermediate People's Court Landmark Class-Action Verdict (2.46B Yuan) CSRC Lifetime Securities Market Ban (Ma Xingtian) |
STEP-BY-STEP SCHEME EXECUTION MECHANICS
4 PHASES| Phase | Execution Step & General Ledger Mechanics |
|---|---|
| Step 01 | 1. Finance staff forged bank deposit slips, electronic transfer receipts, and bank statements to inflate reported cash and bank balances by 29.9 billion yuan ($4.4B USD). |
| Step 02 | 2. Kangmei simultaneously fabricated 20.6 billion yuan in fictitious sales revenue and overstated fixed assets and construction-in-progress. |
| Step 03 | 3. Funds raised from bond and equity markets were secretly routed to related-party entities controlled by Ma Xingtian for real estate and stock speculation. |
| Step 04 | 4. When forced to restate in April 2019, management astonishingly attributed the missing 30 billion yuan in cash to an 'accounting clerical error'. |
FORENSIC JOURNAL ENTRIES & T-ACCOUNT DISTORTIONS
GENERAL LEDGER TRANSACTIONS| Period | Debit (+) Account | Debit ($) | Credit (-) Account | Credit ($) | Forensic Intent & Financial Statement Distortion |
|---|---|---|---|---|---|
| 2016-2018 (Forged Bank Cash & Revenue Inflation) | Cash and Bank Balances (Fictitious) | $4.4B | Sales Revenue & Related-Party Clearing Accounts | $4.4B | Intent: Fabricate liquid cash reserves on the balance sheet while diverting capital to insider real estate projects. Distortion: Overstated cash by nearly 30B yuan while simultaneously issuing expensive short-term commercial paper. |
| Taxonomy | Applicable Scheme Classifications |
|---|---|
| Correlated Schemes |
CHARGED RESPONDENTS & OUTCOMES
1 NAMED PARTIES| Respondent | Role | Disposition & Judicial Outcome | Prison | Civil Penalty | O&D Bar |
|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co., Ltd. | ISSUER | Enforcement order and financial sanctions imposed. | None | $350.0M | No |
RED FLAGS OBSERVED PRIOR TO DISCOVERY
1 EARLY WARNING INDICATORS| Red Flag Indicator | Period Observed | Observed Forensic Anomaly | Diagnostic View |
|---|---|---|---|
| CASH FLOW TO NET INCOME DIVERGENCE | 2019 | Operating cash flow severely diverged from reported earnings | Inspect Metric → |
ENFORCEMENT ACTIONS & PRIMARY DOCKETS
PRIMARY SOURCE CITATIONS| Filing Date | Type & Docket ID | Enforcement Order & Regulatory Findings | Disposition | Primary Record |
|---|---|---|---|---|
| September 20, 2021 | foreign regulator ENF-2019-kangmei-pharma | Enforcement Action: Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'. Securities & Corporate Law Compliance | admitted | Docket Record ↗ |
TIMELINE OF EVENTS
2 CHRONOLOGICAL MILESTONES| Date | Event Category | Chronological Forensic Milestone |
|---|---|---|
| June 1, 2019 | MISSTATEMENT | Material accounting irregularities commenced. |
| September 20, 2021 | ENFORCEMENT | Regulators commenced formal proceedings. |